S7 Ep31: FDA Approval Insights: Pemigatinib in FGFR1-Rearranged Myeloid/Lymphoid Neoplasms
Sep 19, 2022
10:13
forum Ask episode
view_agenda Chapters
auto_awesome Transcript
info_circle Episode notes
Dr Verstovsek discusses the FDA approval of pemigatinib in myeloid/lymphoid neoplasms with FGFR1 rearrangements, the transformative effects of pemigatinib, and the importance of identifying chromosomal abnormalities in patients with this aggressive disease.
OncLive® On Air